Gastrointestinal cancer
Explore our latest news, features and educational resources in this specialist area.
Patients with cholangiocarcinoma set to benefit from life extending treatment
Some people who have cholangiocarcinoma are now set to benefit from life-extending treatment pemigatinib after NICE published final draft guidance recommending it.
#VisualAbstract: Combination therapy using conformation-specific KIT inhibitors associated with clinical benefit in patients with advanced gastrointestinal stromal tumors
SMC accepts treatment for hepatocellular carcinoma
Atezolizumab is accepted for use within NHS Scotland for adult with advanced or unresectable disease who have not received prior systemic therapy.
Three treatments accepted for use within NHS Scotland under the orphan medicine/ equivalent process
The treatments recommended are for chronic fibrosing interstitial lung diseases, mycosis fungoides and Sézary syndrome, and metastatic gastric cancer.
Pembrolizumab recommended for colorectal cancer patients with rare mutations
NICE's draft guidance recommends that treatment with pembrolizumab is stopped at 2 years if there is no evidence that a person’s disease has got worse.
SMC accepts treatment for metastatic colorectal cancer
Encorafenib is recommended, in combination, in adult patients with a BRAF V600E mutation, who have received prior systemic therapy.